Congress-HFA
Congress-HFA

Transthyretin Amyloidosis (ATTR)

Heart Failure Association (HFA) 2026

Congress Details

calanderMay 9-12, 2026

location Barcelona, Spain

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Agenda

10 May, 2026

Coming soon
icon Presentation Type
Moderated poster
time icon Time
08:30 - 09:15 CEST
location icon Location
Moderated ePoster 3
icon Title
Design and rationale of DemonsTTRate: A global, long-term observational study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
mic Presenter

Pablo Garcia-Pavia

CIBERCV & Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain

Audio recording at embargo lift
Coming soon
icon Presentation Type
Moderated poster
time icon Time
15:30 - 16:15 CEST
location icon Location
Moderated ePoster 4
icon Title
Influence of Vutrisiran on Systolic Blood Pressure in ATTR-CM: HELIOS-B
mic Presenter

Awais Sheikh

Royal Free Hospital, London, UK

Audio recording at embargo lift

11 May, 2026

Coming soon
icon Presentation Type
Moderated poster
time icon Time
10:30 - 11:15 CEST
location icon Location
Moderated ePoster 2
icon Title
Treatment with transthyretin-lowering RNA interference therapeutics is not associated with ocular or other clinical events due to vitamin A reduction: Pooled analysis of vutrisiran and patisiran data
mic Presenter

Mathew Maurer

Columbia University, NY, USA

Audio recording at embargo lift
Coming soon
icon Presentation Type
Moderated poster
time icon Time
10:30 - 11:15 CEST
location icon Location
Moderated ePoster 2
icon Title
Effect of vutrisiran in patients with and without atrial fibrillation or flutter: Analysis from HELIOS-B
mic Presenter

Xiaowen Wang

Brigham and Women’s Hospital, MA, USA

Audio recording at embargo lift
Coming soon
icon Presentation Type
Presentation
time icon Time
16:45 - 16:52 CEST
location icon Location
Agora 2
icon Title
Vutrisiran-mediated knockdown of transthyretin in patients with transthyretin amyloidosis
mic Presenter

Vincent Algalarrondo

Bichat University Hospital, Paris, France

Audio recording at embargo lift
Coming soon
icon Presentation Type
Presentation
time icon Time
17:19 - 17:26 CEST
location icon Location
Agora 2
icon Title
Influence of disease modifying therapy on the effectiveness of vutrisiran in transthyretin cardiac amyloidosis
mic Presenter

Arielle Abovich

Harvard Medical School, MA, USA

Audio recording at embargo lift
Coming soon
icon Presentation Type
Presentation
time icon Time
17:36 - 17:44 CEST
location icon Location
Agora 2
icon Title
Consistent efficacy of vutrisiran across sexes in transthyretin cardiac amyloidosis: Evidence from the HELIOS-B trial
mic Presenter

Josephine Mansell

National Amyloidosis Centre, London, UK

Audio recording at embargo lift

12 May, 2026

Coming soon
icon Presentation Type
Moderated poster
time icon Time
08:30 - 09:15 CEST
location icon Location
Moderated ePoster 3
icon Title
Comorbidity burden in transthyretin amyloidosis with cardiomyopathy: Insights from the HELIOS-B trial
mic Presenter

Sarah Birkhoelzer

Harvard Medical School, MA, USA

University Hospitals Dorset, Bournemouth, UK

Audio recording at embargo lift